Research Analysts Set Expectations for Rallybio Q2 Earnings

Rallybio Co. (NASDAQ:RLYB) – Research analysts at HC Wainwright boosted their Q2 2025 EPS estimates for Rallybio in a research note issued to investors on Wednesday, April 9th. HC Wainwright analyst M. Kapoor now expects that the company will post earnings of ($0.23) per share for the quarter, up from their prior estimate of ($0.29). HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Rallybio’s current full-year earnings is ($1.34) per share. HC Wainwright also issued estimates for Rallybio’s Q3 2025 earnings at ($0.21) EPS, Q4 2025 earnings at ($0.23) EPS and FY2025 earnings at ($0.97) EPS.

Rallybio (NASDAQ:RLYB) last released its earnings results on Thursday, March 13th. The company reported ($0.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.02. The firm had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.15 million.

Separately, Citizens Jmp downgraded Rallybio from a “strong-buy” rating to a “hold” rating in a research report on Tuesday. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $9.33.

Rallybio Stock Performance

NASDAQ RLYB opened at $0.25 on Friday. The stock has a 50-day simple moving average of $0.64 and a 200 day simple moving average of $0.89. Rallybio has a twelve month low of $0.22 and a twelve month high of $2.77. The stock has a market capitalization of $10.42 million, a PE ratio of -0.16 and a beta of -1.35.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Northeast Financial Consultants Inc grew its position in Rallybio by 336.5% during the fourth quarter. Northeast Financial Consultants Inc now owns 96,422 shares of the company’s stock worth $93,000 after buying an additional 74,334 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Rallybio by 11.4% in the 3rd quarter. Geode Capital Management LLC now owns 244,986 shares of the company’s stock worth $287,000 after acquiring an additional 24,980 shares during the period. Renaissance Technologies LLC grew its holdings in shares of Rallybio by 9.3% during the 4th quarter. Renaissance Technologies LLC now owns 441,318 shares of the company’s stock worth $424,000 after purchasing an additional 37,618 shares in the last quarter. Allostery Investments LP bought a new stake in shares of Rallybio during the fourth quarter valued at approximately $771,000. Finally, Almitas Capital LLC raised its stake in shares of Rallybio by 48.3% in the fourth quarter. Almitas Capital LLC now owns 1,298,119 shares of the company’s stock valued at $1,246,000 after purchasing an additional 422,685 shares in the last quarter. Institutional investors and hedge funds own 90.34% of the company’s stock.

Rallybio Company Profile

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT.